Exhibit 10.14

CONSULTING AGREEMENT

THIS CONSULTING AGREEMENT (the “Agreement”) is made as of the 29^th day of September, 2014 (the “Effective Date”), by and between Dr. Pinchas Cohen, an individual residing at 16577 Chattanooga Place, Pacific Palisades, CA 90272 (the “Consultant”), and COHBAR, INC., a Delaware corporation with its principal place of business at 2265 East Foothill Blvd., Pasadena, CA 91107 (the “Company”). In consideration of the promises contained herein and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:

1. SERVICES.

(a) During the Consulting Period (as hereinafter defined), the Company hereby engages the Consultant to provide, and the Consultant hereby agrees to provide, such consulting, advisory and related services to and for the Company as described on Exhibit A hereto (the “Consulting Services”). The Consultant shall deliver the Consulting Services at the principal place of business of the Company or at such other location as the Consultant and the Company may mutually agree. The Consulting Services shall be deemed to include any and all time spent by the Consultant traveling for the purpose of performing the Consulting Services. Notwithstanding the foregoing, this Agreement is subject to the University of Southern California Davis School of Gerontology (“University”) Addendum to Consulting Agreement attached hereto as Exhibit B.

(b) The Consultant shall use his best efforts in the performance of the Consulting Services and shall perform the Consulting Services diligently and conscientiously. The Company shall provide such access to its information, property and any other resources as may be required in order to permit the Consultant to perform the Consulting Services.

2. TERM. The term of this Agreement shall commence on the Effective Date and shall continue for twelve (12) months thereafter unless extended by the mutual written agreement of the parties or earlier terminated in accordance with Section 4 hereof (the “Consulting Period”).

(a) The Company shall pay the Consultant a consulting fee (the “Consulting Fee”) as provided in Exhibit A in consideration of the Consultant’s performance of the Consulting Services in accordance with the terms of this Agreement.

(b) If requested by the Company, the Company agrees to reimburse the Consultant for reasonable disbursements made by the Consultant in connection with the performance of the Consulting Services, including travel costs (Business Class if International), telephone and telecopy/facsimile costs, duplicating fees, and delivery services (collectively, “Reimbursable Expenses”).

(c) The Consultant shall provide the Company on a monthly basis with (i) an invoice for the Consulting Fee for the previous month, describing the services delivered during the prior month; and (ii) a listing of Reimbursable Expenses incurred by Consultant and an invoice for reimbursement of such Reimbursable Expenses for the previous month. The Company shall pay such Consulting Fee and reimburse Consultant for such Reimbursable Expenses, as applicable within thirty (30) days following receipt of such invoices by the Company.

(1)

4. TERMINATION; EFFECT OF TERMINATION OR EXPIRATION.

(a) Consultant or Company may terminate this Agreement at any time upon thirty (30) days prior written notice. In the event of such termination, the Consultant shall be entitled to receive (i) any Consulting Fee due but not yet paid as of the effective date of termination and (ii) reimbursement for any Reimbursable Expenses incurred by the Consultant prior to, but not yet reimbursed as of, the effective date of termination.

(b) Upon termination or at any other time upon the request of the Company, the Consultant shall promptly deliver to the Company all drawings, documents and other tangible manifestations of the Consulting Services and any Confidential Information received by the Consultant pursuant to this Agreement, including all copies and reproductions thereof, with the exception of one copy of such material, which may be retained by the Consultant for archival purposes.

(c) The provisions of Sections 4 through 17 hereof shall survive the expiration or termination of this Agreement.

5. CONFIDENTIALITY. It is anticipated that in the performance of the Consulting Services, the Company shall provide to the Consultant or shall give the Consultant access to, certain information that the Company considers confidential or proprietary. The rights and obligations of the parties with respect to such confidential and proprietary information are as follows:

(a) For purposes of this Agreement, “Confidential Information” is defined as any and all information that is or has been disclosed by the Company to the Consultant (including any disclosed prior to the Effective Date), whether directly or indirectly, and whether in writing or orally, and that, by appropriate marking, is identified as confidential or proprietary at the time of its disclosure. In the event that confidential information is provided visually or orally, obligations of confidence shall attach only to that information that is confirmed in writing within thirty (30) days of disclosure as being confidential or proprietary.

(b) The Consultant shall hold in confidence and shall not disclose Confidential Information to any person. The Consultant further agrees that he shall use Confidential Information only for the purpose for which it was disclosed and shall not use or exploit Confidential Information for his own benefit or the benefit of another without the prior written consent of the Company. The Consultant shall disclose Confidential Information received under this Agreement only to persons who have a need to know such Confidential Information in the course of the performance of their duties and who are bound by written agreement to protect the confidentiality of such Confidential Information. If the Consultant becomes aware of any disclosure not authorized hereunder, the Consultant shall notify the Company and take reasonable steps to prevent any further disclosure or unauthorized use.

(c) The Consultant agrees that the Company is and shall remain the exclusive owner of all Confidential Information and all patent, copyright, trade secret, trademark and other intellectual property rights therein. No license or conveyance of such rights is granted or implied to the Consultant by or under this Agreement.

(d) Except as otherwise provided herein, under any other written agreement between Consultant and Company, or under applicable law Consultant shall not be required to treat any information as Confidential Information under this Agreement that: (i) was publicly available prior to the Effective Date or becomes publicly available thereafter through no wrongful act of the Consultant; (ii) was known to the Consultant prior to the date of disclosure and Consultant’s use or disclosure of such information would not violate any rights of the Company or any third party or cause the Company to breach any obligation to any third party; (iii) is disclosed to the Consultant after the Effective Date by a third party having an apparent bona fide right to disclose the information; (iv) the Company gives the Consultant written approval to use or disclose, provided such use complies with the Company’s written instructions; (iv) is disclosed by the Company without restriction on further disclosure; (vi) is independently developed by the Consultant without use of or reference to the Confidential Information; or (vi) the Consultant is obligated to produce it pursuant to an order of a court of competent jurisdiction or a facially valid administrative, Congressional or other subpoena, provided that the Consultant (A) promptly notifies the Company (B) cooperates reasonably with the Company’s efforts to contest or limit the scope of such order and (C) if required to make such disclosure, discloses only that part of the information that is requested and required by law to be disclosed. Nothing in this Section shall be interpreted or construed to grant Consultant any right to make use of or disclose information in violation of applicable law or the Company’s copyright, patent, or other Company intellectual property rights.

(e) The Consultant agrees that he shall not disclose to the Company or make any use of any trade secrets or confidential or proprietary information or those of any other party in performing the Consulting Services, without Company’s and such other party’s prior written consent.

6. INVENTIONS.

(a) All inventions, discoveries, data, technology, designs, innovations and improvements (whether or not patentable or copyrightable) (collectively, “Inventions”) that directly relate to the business or research and development of the Company and that might be conceived, reduced to practice, or made by the Consultant alone or in combination with others in the performance of the Consulting Services or with the use of any Confidential Information or other property of the Company, shall be the sole property of the Company (“Company Inventions”); provided, however, that in no event shall Company Inventions include any Excluded Inventions (as defined below) or any Invention of the Consultant that (a) was conceived, reduced to practice, published or submitted for publication, by the Consultant before the commencement, or after the expiration, of the Consulting Period provided such Invention did not make use of any Confidential Information or other property of the Company; (b) was at any time conceived, reduced to practice, published or submitted for publication independent of the performance of the Consulting Services; or (c) is subject to any obligation of the Consultant to assign such Invention to another party. At the Company’s request and expense, Consultant shall execute whatever documents the Company shall deem reasonable to perfect ownership by the Company in any patents to the extent that such patents claim Company Inventions. The Consultant agrees to assign and hereby assigns to the Company all of the Consultant’s right, title

and interest in and to the Company Inventions and intellectual property rights and applications therefore, in the United States and elsewhere, and appoints any officer of the Company as his duly authorized attorney to execute, file, prosecute and protect the same before any government agency, court or authority.

(b) To prevent untimely or wrongful disclosure or exploitation of the Company Inventions the Consultant shall provide the Company with reasonable prior notice and a copy of (i) any proposed patent or other intellectual property application that claims technology owned by the Company and (ii) any proposed publication or manuscript disclosing previously unpublished Inventions owned by the Company.

7. PUBLICATION AND PUBLICITY. Except for disclosure by Consultant of the fact of his relationship with the Company to parties for whom Consultant does, or desires to, provide professional services the Consultant shall not use the name of the Company or of any staff member or employee or any adaptation, acronym or name by which the Company is commonly known, in any advertising, promotional or sales literature or in any publication without the prior written approval of the Company.

8. OTHER ACTIVITIES OF CONSULTANT.

(a) The Company hereby acknowledges and agrees that the Consultant may engage in providing professional services, which may or may not be similar to the Consulting Services, to other companies or organizations operating in the Company’s field. The Company further acknowledges and agrees that nothing in this Agreement is intended to prevent Consultant from providing such professional services or to impose any covenants not to compete on Consultant.

9. COMPLIANCE WITH UNIVERSITY POLICIES. The Company agrees and understands that Consultant is an employee of the University. In connection with such employment, Consultant has entered into certain agreements with the University relating to ownership of intellectual property rights, conflicts of interest and other matters, and is subject to certain policy statements of the University (collectively, the “University Agreement”). The Consultant represents and warrants that he has and will obtain all approvals and consents, if any, from the University necessary for the Consultant to perform the Consulting Services for the Company under this Agreement and that his performance of the Consulting Services shall not, in any way, violate the University Agreement. The Consultant understands that he is solely responsible and assumes all risk for compliance with the terms of the University Agreement. If any provision of this Agreement is hereinafter determined to be in conflict with the University Agreement, Consultant agrees to immediately notify the Company of the conflict.

10. INDEPENDENT CONTRACTOR STATUS. The Consultant shall perform all services under this Agreement as an “independent contractor” and not as an employee or agent of the Company. The Consultant is not authorized to assume or create any obligation or responsibility, express or implied, on behalf of, or in the name of, the Company or to bind the Company in any manner. The Consultant shall be solely and unconditionally responsible for any and all city, state and federal income taxes, social security withholding taxes and any other self-employment tax obligation relating to any income that the Consultant derives from this Agreement. The

Company and the Consultant shall report payments made by the Company to the Consultant under this Agreement to the appropriate governmental agencies in a manner consistent with the Consultant’s status as an independent contractor.

11. NOTICES. All notices required or permitted under this Agreement shall be in writing and shall be deemed effective upon personal delivery or upon deposit in the United States Post Office, by registered or certified mail, postage prepaid, addressed to the other party at the address shown above, or at such other address or addresses as either party shall designate to the other in accordance with this Section 11.

12. ENTIRE AGREEMENT. This Agreement constitutes the entire agreement between the parties with respect to, and supersedes all prior agreements and understandings, whether written or oral, relating to the Consultant’s engagement by the Company after the Effective Date. This Agreement does not modify, amend or change any obligations the Consultant may have to the Company or the Company’s rights under any agreement relating to intellectual property created by the Consultant and licensed or assigned to the Company prior to the Effective Date. This Agreement may not be modified except by a writing signed by each of the parties.

13. GOVERNING LAW. This Agreement shall be construed, interpreted and enforced in accordance with the laws of the State of California, without giving effect to conflict of laws provisions.

14. SUCCESSORS AND ASSIGNS. This Agreement shall be binding upon, and inure to the benefit of, both parties and their respective successors and assigns, including any corporation with which, or into which, the Company may be merged or that may succeed to any of its assets or business; provided, however, that the obligations of the Consultant are personal and shall not be assigned by him.

15. SEPARABILITY. If any provision of this Agreement is found to be unenforceable, the remainder shall be enforced as fully as possible and the unenforceable provision shall be deemed modified to the limited extent required to permit its enforcement in a manner most closely approximating the intention of the parties as expressed herein.

16. WAIVER. No failure or delay by either party hereto in exercising any right, power or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise thereof preclude any other or future exercise of any right, power or privilege.

17. LIMITATION OF DAMAGES. In no event shall either party be liable to the other for any incidental, special, indirect, punitive or consequential damages arising out of or relating to this Agreement, even if such party or any of its authorized representatives has been advised of the possibility of such damages. Either party’s cumulative liability to the other party on any ground pursuant to this Agreement shall not exceed the annual sum equal to the fees paid or due payable to the other party hereunder.

[Signature Page Follows]

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year set forth above.

COMPANY

EXHIBIT A

Consulting Fee and Services

CONSULTING FEE

$42,000 annually, payable at a rate of $3,500 per month.

CONSULTING SERVICES

In the scope of this contract, the Consultant is likely to perform consulting including, but not limited to, the following services:

EXHIBIT B

USC Davis School of Gerontology Addendum to Consulting Agreement

University of Southern California

Relationships with Industry

1. Purpose

The purpose of this policy is to:

2. Background

USC recognizes that Industry possesses knowledge about the safety and efficacy of pharmaceuticals, medical devices, and medical supplies that may be of value to USC Healthcare Professionals and that may benefit their patients. In addition, USC Healthcare Professionals may have expertise that is beneficial to Industry.

However, in certain circumstances these relationships can improperly influence, or appear to improperly influence, clinical, purchasing or prescribing decisions. In addition, it is a violation of the federal Anti-Kickback laws to knowingly receive anything of value that induces a clinician to use or purchase products/services (e.g., prescription drugs or medical devices) that are paid for by government programs, such as Medicare or Medicaid. (See Exhibit A, a summary of applicable laws and standards, below.)

Fundamentally, interactions with Industry must serve legitimate educational, research and clinical purposes, and contribute to better health care for patients. This policy establishes standards for appropriate interactions with Industry. In addition to the standards established in this policy, it is important for all USC Healthcare Professionals to comply with the university’s Conflict of Interest in Professional and Business Practices policy.

3. Scope

This policy applies to all “USC Healthcare Professionals”, who are defined as:

The policy applies to on-site and off-site interactions with Industry.

1

4. Types of Interactions Covered by this Policy

This policy provides guidelines for the following types of interactions with Industry:

A. Consulting Arrangements and Industry-sponsored Speaking Engagements

This section covers all consulting arrangements with Industry, including participating on advisory committees, giving lectures or other presentations, Industry-sponsored speaking engagements, providing training and advice or other services for payment (collectively, “Consulting Arrangements”). Special considerations for Industry-sponsored speaking engagements (e.g., speakers’ bureaus or promotional presentations) are discussed in Section A.3 below.

A.1 Requirements for Consulting Arrangements

A.1.1 USC Healthcare Professionals are ultimately responsible to ensure that all Consulting Arrangements:

A.1.2 In addition, before signing a Consulting Arrangement, USC Healthcare Professionals should consider whether the request for services has originated from an appropriate unit/division within Industry. For example, Industry marketing representatives generally are not the appropriate unit to engage services that are solely scientific in nature.

2

A.1.3 USC Healthcare Professionals may accept meals, travel and lodging in connection with meetings for consulting services, so long as they are of “modest value” and incidental to the consulting or other services provided. See Exhibit C for guidelines on establishing “Modest Value.”

A.2 Disclosure and Approval of Consulting Arrangements

A.2.1 All Consulting Arrangements must be disclosed to, reviewed and approved by the USC Healthcare Professional’s Department Chair or Chair Designee (the “USC Approver”) before consulting services can be rendered (in the event that the Department Chair or Chair Designee has a conflict of interest, the Chair shall forward the agreement to the Dean or Dean’s Designee for approval. In the event that the Dean has a conflict of interest, the Dean shall forward the agreement to the Provost or the Provost’s Designee for approval). Consulting Arrangements may also require approval of the Dean or his/her designee, as determined at the Dean’s discretion. The USC Approver/s is/are responsible for the following:

A.2.2 USC Healthcare Professionals must disclose to their students, residents and fellows any Consulting Arrangement they may have or have had that relates to Industry products (e.g., device, product, equipment) that are being described, taught or used in an educational or instructional setting (e.g., classroom, operating room, lab).

A.3 Industry-sponsored Speaking Engagements/Lectures

A.3.1 USC Healthcare Professionals may participate as bona fide lecturers at an Industry-sponsored conference if they:

A.3.2 USC Healthcare Professionals are strongly discouraged from speaking as a paid promotional speaker at Industry-sponsored events, i.e. speaker’s bureaus. To the extent a USC Healthcare Professional chooses to engage as a speaker at such Industry-sponsored events, he/she must:

3

B. Gifts, Invitations and Free Meals

B.1

USC Healthcare Professionals may not accept gifts of any kind from Industry, including food, branded items such as pens and notepads, even if such gifts are of nominal value. Existing branded items may not be utilized in patient- care areas and must be removed.

B.2

USC Healthcare Professionals may not accept any item from an Industry representative that is for the Healthcare Professional’s or family member’s personal benefit, such as floral arrangements, artwork, golf balls, sporting bags, or tickets to sporting, musical or other types of entertainment events.

B.3

USC Healthcare Professionals and/or their family members may not accept Industry invitations for free or discounted admission to entertainment events such as plays, sporting events or golf outings, even where some business may be discussed.

B.4

With the exception of food provided in accordance with CE accredited programs, or meals provided in accordance with Section C of this policy, USC Healthcare Professionals may not accept any food or meals from Industry representatives. For example:

B.5

USC Healthcare Professionals may not accept payment or any other remuneration from Industry in exchange for attending any lunch, dinner or reception.

B.6

USC Healthcare Professionals may not accept Industry donations/loans of equipment, devices or supplies, except as follows:

4

These arrangements:

C. Attendance at Industry-sponsored Conferences

C.1

USC Healthcare Professionals may attend Industry-sponsored educational meetings, lectures and conferences containing objective scientific and educational information that promotes evidence-based medicine and scientific research and where support of industry is prominently disclosed. (USC Healthcare Professionals are attending conferences as attendees, and not faculty/lecturers, if they only present a peer-reviewed poster or paper.) USC Healthcare Professionals shall follow these standards when attending Industry-sponsored educational meetings:

C.2

USC Healthcare Professionals may attend modest receptions and meals provided by Industry in connection with educational meetings/conferences. The meals and receptions should be incidental and subordinate to the educational content of the meetings. The meal or reception should be modest in value and conducive to discussion among those participating in the event.

C.3

USC Healthcare Professionals may not “dine and dash” (i.e., take food provided by Industry without actually participating in the educational lecture or accept an Industry representative’s offer to provide a meal without providing educational content).

C.4

A USC Healthcare Professional shall not under any circumstances accept reimbursement for transportation, lodging, meals or incidentals for the cost of his or her spouse or other guest(s).

5

D. Education Grants and Trainee Scholarships

D.1 Education Grants

Education grants may provide funding for valuable activities that are important to the University’s mission. These activities include but are not limited to sponsorship of grand rounds, journal club or morbidity and mortality conferences, all of which are conducted to further education. USC Healthcare Professionals shall comply with the following guidelines when accepting education grants from Industry:

* A bona fide fellowship is one that is ABMS accredited, if accreditation is available for the subspecialty training in question. Where such accreditation is not available (i.e. the subspecialty is not recognized by ABMS for certification purposes), the fellowship must be a formal subspecialty program with clearly identified didactic and clinical requirements where the training elements predominate over patient care as the focus of the program.

D.2 Trainee Scholarships to Conferences

USC recognizes that attendance at educational conferences may further the knowledge of the attendees and benefit USC patients. However, receipt of such funding directly by Trainees from Industry could inappropriately influence medical or other clinical students, residents, fellows and other healthcare professionals in training (“Trainees”), or

6

create the appearance of impropriety. To ensure that Trainees are not inappropriately influenced by Industry, the following guidelines shall apply to Industry funding of Trainee scholarships to educational conferences:

E. Unrestricted Grants

Unrestricted grants, (e.g., grants not provided for educational or other purposes described in this policy), could have the appearance of inappropriately attempting to influence USC Healthcare Professionals. USC Healthcare Professionals may not accept unrestricted grants. Questions regarding unrestricted grants should be directed to the Office of Compliance.

F. Industry-sponsored Research Projects

F.1

All Industry-sponsored research projects must be reviewed and approved by USC’s Health Research Association or the USC Department of Contracts and Grants, and are subject to USC’s research policies generally; see Faculty Issues on USC Policies site, and in particular USC’s Conflict of Interest in Research policy, a copy of which may be obtained at ooc.usc.edu/conflict-interest-research.

F.2

Disclosures of potential or actual conflicts of interest in research must be made to the relevant Institutional Review Board (IRB) and/or Conflicts of Interest Committee (CIRC) per the Conflict of Interest in Research policy and IRB procedures.

F.3

The CIRC and IRB will consult with the Office of Compliance and Department Chair as appropriate, in cases where this policy and the Conflict of Interest in Research policy both may apply to a particular disclosure. (There are circumstances where this policy and the Conflict of Interest in Research policy may overlap but have different objectives. For example, a USC Healthcare Professional may be a Principal Investigator on an Industry-funded research project, but have a Consulting Arrangement that creates an actual or potential conflict of interest as described under the Conflict of Interest in Research policy. The CIRC may review the Consulting Arrangement to confirm that it does not appear to bias the research design, protocol or outcomes. But the Consulting Arrangement also may require review under Section A of this policy to ensure that it does not appear to influence particular prescribing or dispensing habits.)

G. Training and Education Regarding Use of Medical Devices

G.1

To ensure that USC Healthcare Professionals receive appropriate training free from inappropriate influences over their clinical decision-making, prescribing and purchasing decisions, the following policies shall be followed regarding attendance at medical device manufacturer-sponsored training sessions:

7

H. Pharmaceutical Samples, Discounts and Other Reductions in Price

H.1 Use of Samples

H.2 Pharmaceutical Sample Distribution

H.3 Discounts

It is permissible for USC Healthcare Professionals to accept discounts and other price reductions on goods or services only to the extent the discounts and price reductions comply with the federal Anti-Kickback laws and the following:

8

H.4

Under no circumstances may USC Healthcare Professionals charge a patient for a drug sample, or provide a drug sample to a patient, who is covered by a federal or state health care program where the cost of the drug is otherwise included within the payment received from the federal or state health care program.

I. Site Access by Industry Representatives

I.1 Registration

Industry representatives must be registered in USC’s centralized Industry representative tracking system and comply with USC Care Medical Group Policy CL 135 entitled “Site Access by Pharmaceutical and Device Manufacturer Representatives.” As a part of this registration process, representatives are required to:

I.2 Site Access/Pharmaceutical Representatives

Site access by a registered Industry representative may occur only:

Representatives failing to obtain a security pass will be asked to leave the campus.

I.3 Site Access/Device Representatives

It is understood that site access by device manufacturers may be required for training or ongoing device refinement. Site access by a registered Industry representative in this case may occur only:

It is unacceptable for a device representative to be in a patient-care area solely for marketing purposes and with the intent of influencing a USC Healthcare Professional’s treatment decisions.

J. Ghostwriting

The AAMC defines ghostwriting as “the provision of written material that is officially credited to someone other than the writer(s) of the material.” Transparent writing collaboration with attribution between academic and industry investigators, medical writers and/or technical experts is not ghostwriting. It is not permissible for USC Healthcare Professionals, students or trainees to allow their professional presentations to be ghostwritten by any party.

9

K. Recusal from Purchasing Decisions

Every employee of the university must avoid both actual conflicts of interest and the appearance of conflicts of interest and be in compliance with the university’s Conflict of Interest and Ethics Policy and Procedures.

USC Healthcare Professionals are obligated to disclose to the appropriate parties (e.g., Pharmacy and Therapeutics Committees, Chair/Supervisor), any past or current financial interests, management roles or consulting relationships with Industry which are relevant to the product/service under consideration.

USC Healthcare Professionals must recuse themselves from any purchasing deliberations or decisions relevant to the conflicting interests that pertain to the Industry’s products or services when there is an ongoing or current consulting relationship.

5. Enforcement

The Office of Compliance in conjunction with various impacted units is available as a resource for the implementation and interpretation of this policy. All USC Healthcare Professionals are encouraged to call the office should they need assistance or have questions about the policy.

5.1 Faculty and Staff

Sanctions for violations of this policy for faculty will be in accordance with the Faculty Handbook. Sanctions for violations of this policy for staff will be in accordance with the Staff Employment Policies and Procedures. Any disciplinary action against a faculty member or a staff employee under this policy should take into account the scale of the offense, the individual’s intent, and the degree of wrongdoing.

5.2 Students

Sanctions for violations of this policy for students will be in accordance with SCampus.

5.3 Industry

Violation of this policy by Industry representatives will result in disciplinary action, including but not limited to the following:

Exhibit A: Summary of Applicable Law and Standards

It is USC policy to ensure that all interactions with Industry are conducted in conformity with the federal Anti- Kickback laws, in addition to other applicable federal, state and local laws. Generally, the Anti-Kickback laws prohibit paying or receiving anything of value, for which one purpose is to induce the receiver to use, recommend or purchase any products or services that may be paid for by Medicare, Medi-Cal or any other state or federal health care program. Violations of the law are punishable by up to five years in prison, criminal fines up to $25,000, administrative civil money penalties up to $50,000, and exclusion from participation in federal health care programs.

USC policy is informed by the voluntary guidelines developed by the American Medical Association (Ethical Opinion E-8.061), the Pharmaceutical Research and Manufacturers of America “Code of Interactions with Health

10

Care Professionals” (“PhRMA Code”), the Advanced Medical Technology Association’s “Code of Ethics on Interactions with Health Care Professionals” (“AdvaMed Code”), the Office of the Inspector General’s (“OIG”) “Compliance Program Guidance for Pharmaceutical Manufacturers” (“OIG Compliance Guidance”) and the ACCME Standards for Commercial Support (“ACCME Standards”).

In particular, USC seeks to comply with the general principles set forth in the OIG Compliance Guidance and to ensure that no interactions with Industry have the potential to improperly influence clinical decision-making, inappropriately increase Medicare/Medicaid or other insurance costs, increase the risk of overutilization of health care services, or create patient safety or quality of care concerns.

Shown below are links to the voluntary guidelines and government guidance noted above: American Medical Association Ethical Opinion E-8.061

See www.ama-assn.org

PhRMA Code

See www.phrma.org/files/PhRMA Marketing Code 2008.pdf

AdvaMed Code

See www.advamed.org/NR/rdonlyres/61D30455-F7E9-4081-B219- 12D6CE347585/0/AdvaMedCodeofEthicsRevisedandRestatedEffective20090701.pdf

OIG Compliance Program Guidance for Pharmaceutical Manufacturers

See oig.hhs.gov/authorities/docs/03/050503FRCPGPharmac.pdf

ACCME Standards for Commercial Support

See www.accme.org/dir_docs/doc_upload/68b2902a-fb73-44d1-8725-80a1504e520c_uploaddocument.pdf

Medicare Anti-Kickback laws

See www.law.cornell.edu/uscode/html/uscode42/usc_sec_42_00001320—a007b.html

Exhibit B

The following are the USC affiliated faculty practice plan corporations that are “Healthcare Professionals” under this policy (schools and departments that are not faculty practice plan corporations but who interact with Industry, including but not limited to, Dentistry, Pharmacy and the Student Health Center, are subject to the same obligations as the faculty practice plan corporations under this policy):

USC Occupational Therapy Associates, Inc.

USC Physical Therapy Associates, Inc.

USC Care Medical Group, Inc.

Exhibit C: Specific Guidelines for establishing “Modest Value” in Meals, Travel and Lodging

For USC-related activities, “Modest Value” is defined by the Expenditure Manual. Modest value means modest by local standards, but in no event may exceed the following: (1) for out-of-town travel, the maximum value of meals, hospitality, travel (exclusive of plane fare) and lodging should not exceed the maximum rate of USC travel reimbursement for actual expenses, which is set each at a maximum dollar value; and (2) if only certain individual items are provided, those items should not exceed the maximum allowed per item.

For non-USC related activities, we recommend utilizing the USC definition of “modest value” along with the additional guidance provided below:

11

Responsible Office

Office of Compliance

ooc.usc.edu

complian@usc.edu

(213) 740-8258

Issued by

Chrysostomos L. Nikias, Executive Vice President and Provost

Todd R. Dickey, Senior Vice President, Administration

University of Southern California

12